Grifols Balance Sheet Health
Financial Health criteria checks 1/6
Grifols has a total shareholder equity of €7.6B and total debt of €8.6B, which brings its debt-to-equity ratio to 112.6%. Its total assets and total liabilities are €19.7B and €12.1B respectively. Grifols's EBIT is €1.4B making its interest coverage ratio 2.6. It has cash and short-term investments of €849.0M.
Key information
112.60%
Debt to equity ratio
€8.56b
Debt
| Interest coverage ratio | 2.6x |
| Cash | €849.00m |
| Equity | €7.60b |
| Total liabilities | €12.11b |
| Total assets | €19.71b |
Recent financial health updates
Recent updates
GRF: Higher Required Returns Will Still Support Upside From Current Pricing
Analysts have trimmed their price targets on Grifols, with recent research such as the move from €15.00 to €13.50 supporting a modest reduction in our fair value estimate from €15.20 to about €15.08. They are factoring in slightly softer growth and margin assumptions alongside a higher expected discount rate, partly offset by a higher future P/E ratio.
GRF: Execution On Profitability Reset And Higher P/E Will Unlock Upside
Analysts have nudged their fair value estimate for Grifols slightly lower to €21.72 from €21.78, reflecting reduced revenue growth and profit margin assumptions, alongside a higher future P/E, in line with recent Street moves such as Barclays trimming its price target to €13.50 from €15.00. Analyst Commentary Bullish analysts appear to be treating the latest target cut as more of a valuation reset than a shift in long term conviction, with the rating held at Overweight even as the price objective moves to €13.50 from €15.00.GRF: Higher Required Returns Will Still Support Attractive Future Earnings Multiple
Analysts have trimmed their valuation outlook for Grifols, reducing the implied price target from €15.20 to €15.03 as they factor in a higher discount rate and a slightly richer future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: Held broadly steady at €15.20, with only a marginal adjustment to the implied price target in the updated model.GRF: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have modestly reduced their price target on Grifols from approximately 23.00 dollars to 21.78 dollars, citing a higher perceived discount rate that more than offsets slightly stronger long term revenue growth and margin assumptions, along with a lower future price to earnings multiple. What's in the News Grifols has scheduled a Board meeting on September 25, 2025, to approve the creation of a Strategy Committee with an advisory role focused on strategic initiatives and developments, as defined in the Regulations of the Internal Functioning of the Board of Directors and the committee's own regulations (company filing).GRF: Upcoming Strategy Committee Will Support Improved Profit Margins Ahead
Analysts have slightly lowered their price target for Grifols from $15.45 to $15.20, citing minor adjustments to growth projections and profit expectations. What's in the News Grifols, S.A. is holding a Board Meeting on September 25, 2025, to establish a Strategy Committee with an advisory role focused on strategic initiatives and developments (Key Developments).GRF: Rising Margins and Board Initiatives Will Drive Future Performance
Analysts have lowered their price target for Grifols from $16.48 to $15.45, citing modestly reduced revenue growth expectations and a lower future price-to-earnings multiple. This comes despite slightly improved profit margins and a more favorable discount rate.
Biopharma Innovations And Tactical Strengths Propel Future Profitability And Market Expansion
Grifols' focus on innovation and new product development is poised to drive future revenue growth and market expansion.Financial Position Analysis
Short Term Liabilities: GRF's short term assets (€5.1B) exceed its short term liabilities (€2.0B).
Long Term Liabilities: GRF's short term assets (€5.1B) do not cover its long term liabilities (€10.1B).
Debt to Equity History and Analysis
Debt Level: GRF's net debt to equity ratio (101.4%) is considered high.
Reducing Debt: GRF's debt to equity ratio has increased from 92.1% to 112.6% over the past 5 years.
Debt Coverage: GRF's debt is not well covered by operating cash flow (12.2%).
Interest Coverage: GRF's interest payments on its debt are not well covered by EBIT (2.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/02 09:31 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Grifols, S.A. is covered by 31 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |